Adam Dubow Sells 4,319 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Adam Dubow sold 4,319 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total value of $38,482.29. Following the sale, the insider owned 62,626 shares in the company, valued at approximately $557,997.66. This represents a 6.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $8.41 on Thursday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $14.46. The stock has a market cap of $863.51 million, a PE ratio of -5.53 and a beta of -1.25. The stock has a fifty day moving average of $7.68 and a 200-day moving average of $7.06.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.09. The business had revenue of $39.80 million during the quarter, compared to the consensus estimate of $38.20 million. Day One Biopharmaceuticals had a negative return on equity of 32.05% and a negative net margin of 113.53%.The firm’s revenue was down 57.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.38 EPS. On average, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analyst Ratings Changes

DAWN has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Thursday, October 30th. HC Wainwright cut their price target on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Needham & Company LLC reduced their price target on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Piper Sandler increased their price objective on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.43.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors have recently made changes to their positions in DAWN. Federated Hermes Inc. purchased a new position in Day One Biopharmaceuticals in the third quarter worth $39,000. Ameritas Investment Partners Inc. lifted its stake in Day One Biopharmaceuticals by 44.5% during the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the last quarter. Quarry LP purchased a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth about $49,000. Entropy Technologies LP purchased a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth about $67,000. Finally, Prudential Financial Inc. bought a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $69,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.